PULSE BIOSCIENCES, INC. current report, 19 May 2022

Full document

Pulse Biosciences, Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K Current Report, dated May 19, 2022, details the results of Pulse Biosciences, Inc.'s 2022 Annual Meeting of Stockholders. The meeting was conducted virtually via live audio webcast.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.

Material Changes and Voting Results

Stockholders voted on four primary proposals, all of which were approved or ratified:

  • Election of Directors: All seven nominees were elected to serve until the 2023 Annual Meeting. The highest "For" vote count was 18,330,649 for Mahkam Zanganeh, D.D.S., and the lowest was 17,324,926 for Robert W. Duggan.
  • Ratification of Auditors: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 25,725,171 votes "For."
  • Executive Compensation (Say-on-Pay): Stockholders approved the compensation of named executive officers on a non-binding advisory basis with 18,144,288 votes "For."
  • Frequency of Say-on-Pay Votes: Stockholders voted to hold future advisory votes on executive compensation once every three years, with 15,908,724 votes cast for the three-year option.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Key Facts for Investor Verification

  • Verify the total number of shares outstanding to contextualize the voting percentages.
  • Confirm the specific terms of the newly elected directors' tenure and any potential conflicts of interest.
  • Review the full proxy statement for detailed breakdowns of executive compensation packages approved by the vote.
  • Check subsequent filings for the company's financial performance for the fiscal year ending December 31, 2022, as this 8-K contains no financial data.